-
Qizheng Tibetan medicine re declared the phase II clinical application of class 1 new anticancer drug ethane Selene dispersible tablet
Time of Update: 2015-04-15
According to the website of the State Food and Drug Administration (CFDA) on April 15, the processing status of phase II clinical application of the class 1 anti-cancer new drug ethane Selene dispersi
-
Tnp-2092, a class 1 new drug of Danuo medicine, was accepted by CDE
Time of Update: 2015-04-14
Tnp-2092, a class 1.1 new drug of Danuo Pharmaceutical (Suzhou) Co., Ltd., was undertaken by CDE on April 10 and entered the evaluation center, involving the acceptance numbers of cxhl1500175, cxhl150
-
MDM2 inhibitors, a new anticancer drug developed by Hudson, a subsidiary of Hainan Haiyao, is undergoing preclinical research
Time of Update: 2015-04-14
Hainanhai Pharmaceutical Co., Ltd said on April 14 that its holding subsidiary Hudson biomedical Co., Ltd., which holds 70% of the shares, is still in the pre clinical research stage of new anti-cance
-
Hey, AD! Gold mine under the fog of drug research and development
Time of Update: 2015-04-13
The most common Alzheimer's disease is Alzheimer's disease (AD), accounting for about 60% - 80% of the cases of Alzheimer's disease It is a fatal neurodegenerative disease with progressive development
-
Huabang pharmaceutical psoriasis Class 1.5 new drug tazarotene betamethasone cream obtained the production approval
Time of Update: 2015-04-13
According to the information on the website of CFDA on April 13, the status of tazarotene betamethasone cream, a 1.5 dermatological drug of Huabang pharmaceutical, was changed to "certificate preparat
-
CDE drug review weekly report (April 7, 2015 to April 12, 2015)
Time of Update: 2015-04-13
The two drugs that entered the approval process this week are Hebei aierhaitai Pharmaceutical Co., Ltd.'s alprinone hydrochloride injection (cxhs1100154) and Hebei jiupai Pharmaceutical Co., Ltd.'s al
-
The clinical application of dp-vpa, a class 1 antiepileptic drug of Enhua Pharmaceutical Co., Ltd. has been completed
Time of Update: 2015-04-13
According to the information on April 13 on the website of CFDA, the clinical application status of dp-vpa APIs and tablets of class 1 new drug of Enhua Pharmaceutical Co., Ltd is shown as "certificat
-
1. Class 1 new drug Viagra obtained clinical approval; Jilin Yatai increased capital to acquire Weikeli
Time of Update: 2015-04-12
On April 11, Jilin Yatai (Group) Co., Ltd announced that Jiangsu Weikeli Pharmaceutical Technology Co., Ltd had obtained the approval document for clinical trials of drugs In 2015, the third interim B
-
Ly2157299 (gallisertib), an anti-tumor drug, has been approved for clinical use in China
Time of Update: 2015-04-09
Ly2157299 (gallisertib), an antineoplastic drug of Lilly pharmaceutical, was first declared in China in December 2013 and approved for clinical use on March 31, 2015 At present, the processing status
-
The application for uni PTH is under approval
Time of Update: 2015-04-09
Liankang Biology (00690) announced that the new drug application of parathyroid hormone (1-34) isoisomer uni-pth independently developed by the group has been accepted and approved by the State Food a
-
Yangzong Pharmaceutical Co., Ltd. in Qinghai Province has developed the extract of Rehmannia glutinosa "Catalpol" into a new hypoglycemic drug
Time of Update: 2015-04-08
A new research result from Qinghai Provincial Department of science and technology shows that Catalpol, a common ingredient in traditional Chinese medicine Rehmannia glutinosa, can effectively treat d
-
Taiwan one belt, one road to develop new stem cell drugs
Time of Update: 2015-04-05
Xuanjie biotechnology company, led by xuanzhi, the honorary vice chairman of liandian, aims at the revolutionary medical innovation in the next 50 years General manager Xuanchang disclosed on the 5th
-
Tailing pharmaceutical 1.1 new drug - alternative Library of "major new drug creation" special project of the Ministry of science and technology
Time of Update: 2015-04-02
Thaling pharmaceutical announced that the national 1.1 new drug, xitique [niacin (Yuetai) injection], applied by the group for the treatment of "myelodysplastic syndrome (MDS)" and industrial transfor
-
"Ambroxol", a new heavyweight drug of Haizheng pharmaceutical industry, is expected to be approved within 1-2 months
Time of Update: 2015-04-01
According to the information on April 1 on the website of the State Food and Drug Administration (CFDA), the declaration status of the heavyweight new drug "ambano" (recombinant human tumor necrosis f
-
CDE drug review weekly report (March 23-29, 2015)
Time of Update: 2015-03-30
Among the 28 drugs approved to enter the approval process this week, 27 chemicals and 1 pharmaceutical excipient Among the 27 chemical drugs, there are no imported drugs, and 6 categories account for
-
Xinlitai plans to apply for 10 clinical approvals (including 3 biological drugs) this year
Time of Update: 2015-03-30
Kevin sing ye, general manager of xinlitai, disclosed to investors that in 2015, the company plans to apply for clinical approval documents for 10 new products (including 3 in the field of Biopharmace
-
Taiantang Shezhi shenhuang ointment obtained new drug certificate
Time of Update: 2015-03-28
Recently, taiantang received the new drug certificate and drug registration approval document of shezhishenhuang ointment issued by the State Food and drug administration According to the drug adminis
-
The application of anti IL6 monoclonal antibody of yaominglikang in the treatment of rheumatoid arthritis was accepted by CFDA
Time of Update: 2015-03-28
Wuxi yaominglikang biotech Co., Ltd., a joint venture of Wuxi yaominglikang biotech Co., Ltd., has successfully applied to China food and Drug Administration (CFDA) for the clinical trial of new drugs
-
"Lobaplatin", a new antitumor drug of Yibai pharmaceutical, has obtained clinical approval
Time of Update: 2015-03-26
Organized and implemented by Guizhou Yibai Pharmaceutical Co., Ltd., the national first-class anti-tumor new drug, patent protection product, and national medical insurance catalog product - "lobaplat
-
67 Chinese listed pharmaceutical companies increased their R & D investment by 25% in 2014
Time of Update: 2015-03-26
In the pharmaceutical industry, R & D capability is an important evaluation index to measure the future development of a pharmaceutical enterprise The proportion of R & D expenditure to operating reve
